Study S003301

A Randomised, Double-blinded, Multiple-dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC9204-1706 in Subjects Being Overweight or With Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT03661879
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 60
Start: 2018-09-12
Primary completion: 2019-09-05
Lead sponsor: Novo Nordisk A/S
Conditions: Metabolism and Nutrition Disorder; Obesity
Interventions: DRUG:NNC9204-1706; DRUG:Placebo (NNC9204-1706)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1208-7677

Registered primary outcomes

Number of treatment emergent adverse events (TEAEs) [Days 1-84]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0029056	A once-daily GLP-1/GIP/glucagon receptor tri-agonist (NN1706) lowers body weight in rodents, monkeys and humans. Finan B, Molecular metabolism	2025	Preclinical	PMID 40139439 DOI	cites ClinicalTrials.gov:NCT03661879